Sydney, May 18, 2026, 07:06 AEST
- Cochlear last traded at A$96.33 on Friday, up 0.95% on the day but down 3.6% from the previous Friday’s close.
- The ASX cash market was in pre-open at the dateline; normal trading starts at 09:59:45 Sydney time.
- Investors are still testing April’s profit warning, when Cochlear cut FY26 underlying net profit guidance to A$290 million-A$330 million.
Cochlear Ltd heads into Monday’s ASX open with little room for drift after the hearing-implant maker gave back ground last week, closing Friday at A$96.33. The shares rose 0.95% in the last session but fell 3.6% from A$99.89 a week earlier, based on historical prices.
That matters now because the market is still deciding whether last month’s collapse was a clean reset or the start of a longer earnings problem. Reuters reported Cochlear shares fell 40.7% on April 22, their worst session ever, after the company slashed its annual earnings outlook on weak developed-market demand and Middle East uncertainty.
Normal trading had not begun at the dateline. The ASX cash market runs a pre-open phase from 07:00 to 09:59 Sydney time, when brokers can enter orders but ASX Trade does not match them; continuous trading starts just before 10 a.m.
Cochlear’s problem is not hard to state. Cochlear implants — surgically implanted electronic devices that can help provide sound to people with severe hearing loss — have faced softer adult and senior demand in developed markets, where surgery volumes depend on referrals, hospital capacity and patient willingness to go ahead with treatment.
The April cut was severe. Cochlear now expects FY26 underlying net profit, its adjusted profit measure, of A$290 million-A$330 million, down from prior guidance of A$435 million-A$460 million; second-half sales growth is expected at 2%-6% in constant currency, meaning exchange-rate moves are stripped out.
Chief Executive Dig Howitt said adult and senior hearing loss was still treated as a “discretionary intervention,” and said the company’s strategy was to “medicalise hearing loss” — in plain terms, to push treatment to be seen as a core health need, not a nice-to-have. He also said the Nucleus Nexa system had seen “strong adoption” and that “market share has been improving.”
There were offsets, but they were not enough to calm the tape. Cochlear said services revenue rose 13% in constant currency in the third quarter, helped by a larger installed base and product retirements, while acoustics revenue grew 11%.
Analysts have not treated the warning as just a one-off miss. Morningstar analyst Shane Ponraj wrote that the headwinds “appeared more structural,” cut Cochlear’s fair value estimate by 51% to A$110, and said he expected “lower earnings growth for longer.” Morningstar
The broader tape gave only limited cover. The S&P/ASX 200 fell 1.3% last week, from 8,744.40 on May 8 to 8,630.80 on Friday, while the S&P/ASX 200 Health Care index dropped 8.1%, hurt by a heavy sector selloff. Cochlear fell less than the sector, but that is cold comfort after April’s reset.
The competitive read-across is mixed. Sonova, whose Advanced Bionics unit competes in cochlear implants, said the worldwide implant market still grows around 8% a year and has significant long-term potential, but Reuters reported Sonova shares fell in March as it faced a slower hearing-aid market, intense competition and weaker peer signals from Demant and Amplifon.
For the week ahead, traders will watch whether Cochlear can hold the mid-A$90s area rather than wait for a scheduled company event. The next date listed on Cochlear’s investor calendar is its full-year results announcement on Aug. 18.
The risk cuts both ways. If weak surgery volumes are delayed rather than lost, and if Nexa adoption keeps share moving higher, the stock may find a floor; but if insurer pressure, hospital bottlenecks and Middle East order risk keep weighing on sales, Cochlear may struggle to prove April was the last downgrade, especially with a stronger Australian dollar already flagged as an earnings drag.
